scispace - formally typeset
G

Giuseppe Minniti

Researcher at University of Siena

Publications -  219
Citations -  10214

Giuseppe Minniti is an academic researcher from University of Siena. The author has contributed to research in topics: Radiation therapy & Radiosurgery. The author has an hindex of 50, co-authored 189 publications receiving 7617 citations. Previous affiliations of Giuseppe Minniti include Sapienza University of Rome & The Royal Marsden NHS Foundation Trust.

Papers
More filters
Journal ArticleDOI

Whole brain reirradiation and concurrent temozolomide in patients with brain metastases

TL;DR: In the respect to the small number of treated patients, repeat WBRT plus concomitant temozolomide may be a treatment option in selected patients with multiple brain metastases to improve or maintain neurological conditions and quality of life with acceptable toxicity.
Journal ArticleDOI

The mean striatal 18 F-DOPA uptake is not a reliable cut-off threshold for biological tumour volume definition of glioma

TL;DR: In the authors' opinion, the recommendation to use the mean basal ganglia uptake as the sole reference standard for definition of tumour volume is not evidence-based and could be misleading.
Journal ArticleDOI

Current status and recent advances in resection cavity irradiation of brain metastases.

TL;DR: In this article, the authors provide a clinical overview on current status and recent advances in resection cavity irradiation of brain metastases, focusing on relevant strategies that can improve local control and minimize the risk of radiation-induced toxicity.
Journal ArticleDOI

Impact of different treatment approaches on pregnancy outcomes in 99 women treated for Hodgkin lymphoma.

TL;DR: No significant associations between pregnancy outcomes and therapeutic approaches were found and the infradiaphragmatic radiotherapy showed no statistical association with miscarriages, premature birth, and low birth weight at term when compared with other therapeutic approaches.
Journal ArticleDOI

Human pituitary tumours express the bHLH transcription factors NeuroD1 and ASH1.

TL;DR: NeuroD1 is differentially expressed in PA and its possible ontogenetic and/or pathogenetic implications in non-corticotroph PA are discussed; ASH1 is a neuroendocrine marker whose expression is largely conserved in normal and neoplastic pituitary cells.